书呆子
医学
格尔德
胃肠道
临床试验
疾病
胃肠病学
内科学
回流
重症监护医学
药理学
作者
Asif Hossain Anik,Farhana Alam Proma,Pranoy Saha,Sabarni Sarker
出处
期刊:Current drug research reviews
[Bentham Science]
日期:2024-03-01
卷期号:16 (1): 11-17
标识
DOI:10.2174/2589977515666230428140741
摘要
Abstract: Potassium-competitive acid blockers (P-CABs), such as tegoprazan, are a new and diverse class of drugs that can completely block the potassium-binding site of gastric H+/K+ ATPase, potentially overcoming the limitations of proton-pump inhibitors (PPIs). A number of studies have compared the effectiveness as well as the safety profile of tegoprazan to PPIs and other P-CABs for the treatment of gastrointestinal diseases. The current review study evaluates the published works of literature related to clinical pharmacology and clinical trials of tegoprazan for the treatment of diseases related to the gastrointestinal tract. According to the publications included in the study, tegoprazan was found to be safe and well-tolerated and can be used to treat a group of gastrointestinal diseases, including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), and H. pylori combination therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI